![](https://cdn.sanity.io/images/0vv8moc6/neurolive/f789749737f1934b34d0322540d51cab0a411fad-300x300.png?fit=crop&auto=format)
Alzheimer Agent T3D-959 Demonstrates Disease-Modifying Effects in Phase 2 PIONEER Trial
In a new analysis of the phase 2 PIONEER trial (NCT04251182), treatment with investigational T3D-959 (T3D Therapeutics) resulted in statistically significant impacts on the study’s co-primary end points, in addition to improvements in other Alzheimer …